




Contents lists available at ScienceDirect

European Journal of Internal Medicine

journal homepage: www.elsevier.com/locate/ejim

Review Article

Comprehensive management of pneumonia in older patients

Alain Putot^a, Nicolas Garin^{b,c}, Jordi Rello^{d,e,f,i}, Virginie Prendki^{g,h,*} , on behalf of the European Study Group of Infections in the Elderly Patients (ESGIE).

^a Médecine Interne et Maladies Infectieuses, Hôpitaux du Pays du Mont-blanc, Sallanches, France

^b Department of Internal Medicine, Riviera-Chablais Hospitals, Switzerland

^c Department of Medicine, Geneva University Hospitals, Switzerland

^d IMAGINE, UR-UM 107, University of Montpellier, Division of Anaesthesia Critical Care, Pain and Emergency Medicine, Nîmes University Hospital, Nîmes, France

^e Medicine Department, Universitat Internacional de Catalunya, Spain

^f Clinical Research Pneumonia and Sepsis (CRIPS) Research Group-Vall d'Hebron Institute Research (VHIR), Barcelona, Spain

^g Division of Internal Medicine for the Aged, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland

^h Division of Infectious Diseases, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland

ⁱ Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain

ARTICLE INFO

Keywords:

Pneumonia
Diagnosis
Treatment
Complications
Older people
Prevention

ABSTRACT

Pneumonia is a leading cause of death and functional decline in the older population. Diagnosis of pneumonia conventionally includes the presence of respiratory signs and symptoms, systemic signs of infection and a radiographic demonstration of lung involvement. Pneumonia diagnosis in the very old patient is compromised by atypical and unspecific presentation, resulting in a high proportion of false positive diagnosis. Chest radiograph is frequently of low quality and inconclusive in older patients. Computed tomography scan and chest ultrasound may provide valuable diagnostic confirmation in uncertain cases. Bacterial pneumonia has been mainly studied, but viruses, among which influenza, SARS-CoV-2, and respiratory syncytial virus, are increasingly recognized as major players. The decision to treat pneumonia is usually based on a triple assessment of diagnostic probability, disease severity and the general assessment of the patient (frailty, comorbidities, place of living, and goals of care). Antimicrobial treatment is probabilistic, targeting common pathogens. The optimal antibiotic treatment depends on epidemiological data, setting of acquisition, comorbidities, risk factors for methicillin-resistant *Staphylococcus aureus*, *Pseudomonas aeruginosa*, or aspiration pneumonia, and severity. Recent controlled trials have demonstrated the non-inferiority of short regimen in non-severe community acquired pneumonia, even in older individuals and a five-day antibiotic treatment is recommended in case of clinical improvement. Pneumonia management in older patients requires a comprehensive approach, including control of comorbidities (particularly cardiovascular), nutritional support, rehabilitation, and prevention of aspiration. Finally, pneumonia may be a pre-terminal event in many patients, requiring advanced-care planning and prompt instauration of palliative management.

1. Introduction

Pneumonia is a bacterial, viral, fungal, or parasitic infection of lung parenchyma, resulting in significant local and systemic inflammation. Pneumonia is the leading infectious cause of hospitalization and death worldwide. In high-income countries, older individuals are particularly affected [1]. Pneumonia is classified as community acquired (CAP), nursing home acquired (NHAP), hospital acquired (HAP), or associated with mechanical ventilation (VAP) (Fig. 1) [2]. Aspiration pneumonia (AsP) is a distinct form of pneumonia that develops in patients with

dysphagia, or when macro aspiration of oropharyngeal content is obvious. AsP is an infection caused by specific microorganisms and the main form of pneumonia in older frail patients, whereas chemical pneumonitis is an inflammation due to the acidity of gastric contents. [3] Pneumonia in the immunocompromised host has many specific aspects and is outside of the scope of this review.

Though antibiotics are highly effective in killing most usual bacterial pathogens, the mortality remains far higher than in urinary or digestive tract bacterial infections. This can in part be attributed to pneumonia being a frequent terminal event in the very old (the widely quoted “old

* Corresponding author.

E-mail address: virginie.prendki@hug.ch (V. Prendki).

<https://doi.org/10.1016/j.ejim.2025.02.025>

Received 29 October 2024; Received in revised form 8 February 2025; Accepted 18 February 2025

Available online 27 February 2025

0953-6205/© 2025 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).




Fig. 1. Pathophysiological and acquisition-site classifications of pneumonia.

man's friend") [1,4]. In 2019, respiratory infections caused an estimation of 2.18 million deaths worldwide, half of them in adults over 70 [1]. Mortality rises steeply with age, from 5 % in <65, to 14 % in >80; further increasing to 20 % and 43 % respectively in the presence of comorbidities [5]. Long-term mortality is also increased, 1 in 3 adults dying the year following an hospitalisation for CAP [6]. Mortality in patients with AsP is twice as high as in patients with non-aspiration CAP, maybe due to a higher prevalence of severe comorbidities [3,7].

The higher incidence of CAP and higher mortality in older age are explained by age-related changes affecting the respiratory tract and the immune system. Accumulating comorbidities and ceiling decisions in the level of care (e.g. not providing full life support in shock or respiratory failure) are other contributors.

2. Pathogens

Many microorganisms can cause pneumonia, though bacterial pneumonia has been mostly studied. However, viruses are increasingly recognized as a major player, as recently highlighted by the Covid-19 pandemic.

Main microbiological aetiologies are presented in table 1. *Streptococcus pneumoniae* is the most common bacteria isolated from older patients. However, its incidence is declining in Western countries, probably secondary to pneumococcal vaccines and decrease in smoking prevalence. In contrast, there is an increase in the relative incidence of *Haemophilus influenzae* [8,9] and *Moraxella catharralis*. *Staphylococcus aureus* and *Enterobacteriaceae* are frequent in older patients, likely

because of the frequency of AsP [3]. While nursing-home patients frequently present with Gram-negative pneumonia, these infections are rare (around 3 %) in home-dwelling patients aged over 80 year [10]. *Mycoplasma pneumoniae* were less frequently found than in younger patients until the recent epidemic [8,9,11]. Legionellosis is frequent in very old patients [12], and should be systematically considered in severe pneumonia or evocative clinical context (acquisition in summer or fall, hyponatremia, fever > =39.5 C) [13]. Identification of *Legionella spp* has significant consequences for treatment, as it is naturally resistant to beta lactams. Antibiotic-resistant pathogens, such as methicillin-resistant *Staphylococcus aureus* (MRSA) and *Pseudomonas aeruginosa*, should be considered in case of antimicrobial failure, especially in patients dwelling with chronic respiratory disease, in intensive care settings. Community-acquired MRSA represents an uncommon cause of pneumonia in older adults [14]. Multidrug resistant *P. aeruginosa* should be considered among older with non-cystic fibrosis bronchiectasis, particularly among women [15]. Factors predisposing patients to infection with Gram-negative multi-drug resistant pathogens are prior colonization with a resistant bacteria, recent hospitalization, and treatment with parenteral antibiotics within the last 90 days [16]. Probabilistic regimen should be adapted to local epidemiology when these factors are present. According to recent data, anaerobes are no more frequent in AsP than in other forms of pneumonia [17]. *Mycobacterium tuberculosis* is the most common etiology, followed by *S. pneumoniae*, in low-middle income countries [18]. Secondary to the dissemination of molecular diagnostic techniques, influenza, SARS-CoV-2 and respiratory syncytial virus (RSV) have been identified as frequent causes of pneumonia during epidemics,

Table 1

Main pathogens involved in pneumonia according to pathophysiology and place of acquisition.

| Aspiration Pneumonia | | Airborne Pneumonia | |
|---------------------------------|--|----------------------------|--|
| Community acquired pneumonia | - <i>Enterobacteriaceae</i> - Methicillin-sensitive <i>Staphylococcus aureus</i> | Interhuman transmission | - <i>Streptococcus pneumoniae</i> - <i>Haemophilus influenzae</i> - <i>Moraxella catarrhalis</i> - <i>Chlamydomytila</i> spp. - <i>Mycoplasma pneumoniae</i> - Respiratory viruses (influenza virus, SARS-CoV-2, respiratory syncytial virus, parainfluenza virus, human metapneumovirus, rhinoviruses, common human coronaviruses) |
| Nursing-home acquired pneumonia | - <i>Anaerobes</i> | | - <i>Mycobacterium</i> spp. - <i>Pneumocystis jirovecii</i> - <i>Aspergillus</i> spp. - <i>Legionella</i> spp. |
| Hospital acquired pneumonia | - <i>Enterobacteriaceae</i> - Methicillin-resistant or resistant <i>Staphylococcus aureus</i> | Environmental transmission | |
| Ventilator-associated pneumonia | - <i>Pseudomonas aeruginosa</i> - <i>Stenotrophomonas</i> spp. and <i>Acinetobacter</i> spp. - <i>Anaerobes</i> - Viruses (SARS-CoV-2, influenza, RSV) | | |

with older adults being an important target for RSV [19]. They are preventable with vaccination, and specific treatment may be administered for influenza (oseltamivir, baloxavir) and SARS-CoV-2 (remdesivir, nirmatrelvir/ritonavir). Molecular test performance also has identified *Pneumocystis jirovecii* as a cause of pneumonia among patients with acute respiratory failure [20], perhaps associated with immunosenescence.

3. Diagnosis

3.1. Clinical signs and symptoms

Diagnostic uncertainty prevails in the majority of cases of suspected pneumonia, especially in older patients. This translates in half the patients hospitalized for pneumonia having discordant diagnoses from initial presentation to discharge [21]. As for younger patients, the most common symptoms are acute cough, dyspnoea, chest pain and sputum. However, the triad of cough, fever and dyspnoea is absent in half the patients with pneumonia [22]. In older patients, pneumonia may present with acute development of geriatric syndromes (fall, delirium, decline of general condition, new incontinence) without classic respiratory or infectious manifestations. The poor specificity may lead to two common pitfalls in this age group: delayed diagnosis and over-diagnosis. Atypical presentation is a marker of poor prognosis [23,24].

3.2. Lung imaging

Radiologic imaging is needed to confirm parenchymal invasion, and





Fig. 2. Chest X-ray (A) and CT scan (B) in an 85-year-old patient presenting with a febrile cough. While the X-ray was compatible with the initial diagnosis of bacterial pneumonia, the CT scan corrected the diagnosis to that of left heart failure. Blood and urine cultures confirmed the extra-pulmonary origin of the fever (pyelonephritis with bacteraemia).

allows localisation of lung injury, extent of disease, and complications. Chest X-ray (CXR) is the main imaging modality used. However, it may be impossible to obtain high quality CXR (bedridden patients, lack of cooperation in delirium) and identification of lung infiltrate can be jeopardized by heart failure, deformation of the rib cage, emphysema, or sequelae (Fig. 2). Consequently, inter-observer agreement on the interpretation of CXR for the diagnosis of pneumonia is poor [25]. Compared with chest CT, sensitivity of CXR is 43–65 % and specificity 93 % [26, 27].

Chest CT can be done with a low radiation dose and without injection of iodinated contrast. It has a higher diagnostic yield. In a prospective study of patients over 65, it was particularly useful for ruling out pneumonia (Fig. 2). The impact was greatest in patients with intermediate pre-test probability (Fig. 3) [28]. However, availability of CT-scan may be limited, and associated costs are a concern for such a frequently suspected disease.

Lung ultrasound (LUS) is an attractive alternative increasingly used. It is a quick, non-irradiating, imaging modality that can be used at the patient's bedside, in the outpatient practice or in the emergency department by non-radiologists (point-of-care, POCT, if available). LUS




Fig. 3. Radiological diagnostic algorithm for pneumonia in older patients.

may be effective when performed by a suitably trained observer [29]. LUS was more sensitive than CXR (92 % vs 47 %) in an acute geriatric unit, with comparable specificity (94 % vs 93 %) [30]. POCT LUS helped discriminate pneumonia from other diagnoses (e.g. acute heart failure or pleural disease) in emergency and internal medicine wards. However, evidence is scarce in the geriatric setting [31]. The learning curve for LUS is steep, meaning that it can be easily taught to a large number of clinicians. [31] Whether improvement in diagnostic accuracy translates in a clinical benefit has still to be demonstrated. Another concern relates to the performance of LUS in a real-world setting when examinations are done by less expert teams.

The ongoing OCTOPLUS trial compares diagnostic, clinical and

economic outcomes in older patients randomized to diagnostic strategies based on CXR, CT scan and POCT LUS [32].

3.3. Biomarkers

The added value of C reactive protein (CRP) or procalcitonin (PCT) to clinical signs and symptoms is low [33,34]. In a meta-analysis of patient-level data, adding CRP to clinical data improved the area under the receiver operating characteristic curve only by 0.075 [35]. Newly proposed biomarkers (e.g. neopterin, Serum amyloid A) are not better than CRP [27]. U.S. guidelines do not recommend the use of PCT for the diagnosis of CAP and stress that biomarkers should always be

interpreted in a clinical context [16]. Although CRP has an excellent negative predictive value in pneumonia [36], it may show a delayed increase during a bacterial infection, resulting in false-negative results in the early stages of the disease [37]. Moreover, some conditions are associated with artificially lower levels, such cirrhosis and hypoproteinaemia or immunosuppressive drugs [66] [67]. Another challenge seems to be the differentiation between inflammation and infection using CRP [68]. Among influenza, hospital mortality has been associated with a phenotype combining immunoparalysis with hyperinflammation which has been identified by determining ferritin and HLA-DR expression [38]. B-D-Glucan has been used for the diagnosis of *Pneumocystis jirovecii* pneumonia [20]. A further concern is the underrepresentation of older patients in most studies. Older patients may have higher baseline levels of inflammatory biomarkers due to chronic inflammation associated with comorbidities or the ageing process, hence lowering their accuracy to diagnose pneumonia [39].

3.4. Microbiological samples

Recommendations for microbiological samples collection vary according to the clinical context and severity of the disease. Even with extensive sampling, the pathogen is rarely identified, and identification will often not alter the antimicrobial treatment [40]. In patients hospitalised for pneumonia, it is proposed to obtain two pairs of blood cultures and good quality sputum samples before administration of antibiotics in patients able to expectorate. The latter is particularly recommended in patients with chronic respiratory disease. Collection of the samples should not delay the administration of antimicrobials. Urine antigen testing for *Legionella pneumophila* is recommended in evocative or severe cases. A urine antigen test for *Streptococcus pneumoniae* is recommended in severe [16,41,42] or, for some guidelines, moderately severe [41,42] CAP, as positivity may help narrowing the antibiotic spectrum.

If Methicillin-resistant *Staphylococcus aureus* (MRSA) is suspected, a negative nasal swab for MRSA detection by PCR may allow to stop anti-MRSA therapy [43].

Testing for SARS-CoV-2, and influenza should be considered in time of epidemics since the results will affect the treatment. Testing for other respiratory viruses frequently found in older patients such as RSV may allow antibiotics sparing and implementing prevention measures in nursing-homes and hospitals. Rhinovirus and metapneumovirus are frequent in inter-epidemic periods of influenza [44]. Bronchoalveolar lavage is rarely performed in older patients and is reserved for patients hospitalised in intensive care units or for whom probabilistic treatment has failed.

Testing for tuberculosis is justified in suggestive clinical or radiological presentations, including a subacute or chronic course, weight loss, haemoptysis, or cavitory infiltrates in developed countries and systematically in LMIC. Due to insufficient accuracy, tuberculin skin test and interferon-gamma-releasing assays have no place for the diagnosis of active tuberculosis [45].

3.5. Prognostic assessment

The severity of infection is assessed based on clinical evaluation and often comforted by the use of validated prognostic scores. The most used are the Pneumonia Severity Index (PSI), based on 20 demographic, clinical and biological characteristics [46], and CURB-65, a score that incorporates confusion, urea >7 mmol/L, respiratory rate >30 min, blood pressure <90 mmHg (systolic) or <60 mmHg (diastolic), and age ≥65 years [47]. Their performance in predicting mortality decreases with age, probably because they do not account sufficiently for comorbidities. [48,49]. SMART-COP score and ATS criteria may be used to predict the need for intensive or vasopressor support [16,50]. Many scores based on comorbidities, functional status, frailty, and sometimes combining laboratory data have been published, and need further

Table 2

First-line probabilistic antibiotic regimens recommended by recent National guidelines for non-severe community acquired pneumonia in patient aged over 75, without allergy or risk factor for resistant pathogens.

| Antibiotic regimen | Outpatient | Inpatient (outside ICU) |
|--|--|---|
| Monotherapy | | |
| Penicillin G | | Europe [41] |
| Amoxicillin | Australia [116], Europe, Great-Britain [42], Korea [117] | Europe |
| Amoxicillin-clavulanate / Ampicillin-sulbactam | China, France [118], Germany [119], Japan [120], Korea, South Africa [121] | Brasil [122], Europe, France, Germany, Japan, Korea, South-Africa |
| Doxycyclin | Australia, Europe | |
| Levofloxacin / Moxifloxacin | Europe, France, Korea, Spain [123], USA [16] | Brasil, Europe, France, Korea, Spain, USA |
| Oral Cephalosporins | China, Korea, South-Africa | South-Africa |
| IV Cephalosporins | France | Brasil, Europe, France, Germany, Korea, South Africa, Japan |
| Combination therapy | | |
| Penicillin G -Macrolides | | Australia, Europe |
| Amoxicillin-Macrolides | Brasil, Spain | Great Britain, Europe |
| Amoxicillin-Doxycyclin | | Australia |
| Amoxicillin-clavulanate-Macrolides | Brasil, China, Korea, Spain, USA | Brasil, Europe, Germany, Spain, USA |
| Oral Cephalosporins-Macrolides | China, Korea, Spain, USA | |
| IV Cephalosporins-Macrolides | | Brasil, Europe, Germany, Spain, USA |

ICU: Intensive Care Unit.

validation [51–53].

4. Antibiotic treatment

The use of antibiotics in the management of pneumonia varies considerably from country to country. These variations stem from different thresholds to accept the risk of antibiotic therapy failure, and of the appreciation of the microbiological impact of antibiotic therapy at the individual and societal level. Accordingly, there are wide variations in national guidelines (table 2), which cannot be explained by microbiological variations alone. Current recommendations state that antibiotic treatment should be started as soon as the diagnosis is made. [41] However, the wish to treat early is in tension with the accuracy of the diagnosis, prompt treatment being associated with overdiagnosis, and if no sepsis, treatment can be deferred to complete the diagnostic path while continuing to monitor the patient [54]. Treatment effectiveness should be assessed after 72 h. The therapeutic strategy needs to account for the frequent diagnostic uncertainty; in the absence of severe disease, antibiotic therapy should be stopped as early as possible when the probability of pneumonia is low or when another diagnosis is more likely. Whenever possible, the oral route, which has shown equivalent efficacy with a lower iatrogenic risk, should be preferred [55,56]. The management of pneumonia in older patients has its own specific features, mainly due to the age-related changes in the upper airway's microbiota, as aspiration is the main pathophysiological pattern in this age group. Use of subcutaneous perfusion has an important role among elderly with therapeutic limitations [57]. We refer the readers to comprehensive recent reviews on challenges in optimization of antibiotics [57–59] to be applied among older adults. Internists should partner with geriatricians, infectious disease specialists, pneumologists and pharmacists to improve patients care [57,60].

4.1. Choice of empiric treatment

In most countries, the preferred probabilistic antibiotic treatment relies on beta-lactam drugs, frequently amoxicillin / clavulanate. In cases of true allergy, levofloxacin or moxifloxacin are the most recommended alternative. Fluoroquinolones are not recommended as a first-line treatment because of the rapid acquisition of bacterial resistance, the major impact in the selection of multidrug resistant pathogens, and adverse effects which, although rare, are potentially severe (torsade de pointes, tendon rupture, encephalopathy) [61,62]. The European Federation of Internal Medicine has published an adaptation of CAP guidelines to the internal medicine setting [63].

Table 2 presents recommendations issued by local societies in different countries. Whether combination antibiotic therapy should be preferred to monotherapy is still controversial [64]. Combination antibiotic therapy is recommended in several guidelines for moderately severe CAP (hospitalized in medical wards), [16] [42], though monotherapy with beta-lactams being non-inferior in terms of 3-month mortality in a large cluster-randomised trial [65]. However, a randomised trial failed to demonstrate the non-inferiority of monotherapy in patients hospitalised for pneumonia to reach clinical stability by day 7. Of note, non-inferiority was achieved once the most severe forms (PSI category 4 or more) or infections with atypical bacteria had been excluded [66].

In severe pneumonia, i.e. patients usually admitted to intensive care settings, combination antibiotic therapy is recommended in all guidelines. The rationale is to broaden the spectrum with an antibiotic covering intracellular pathogens (macrolides or fluoroquinolones) [26]. The immunomodulatory effect of macrolides could also be beneficial, which explains why macrolides are preferred over fluoroquinolones in the latest European recommendations [26]. However, macrolides and fluoroquinolones are associated with increased risk of cardiac arrhythmia [67], and macrolides have a potential for drug-drug interactions, which can be identified using adequate interaction checkers, and prevented, adjusting multiple drug regimens [57].

Of note, antibiotic resistance is lower in Northern Europe than Western Europe, where countries such as Italy and Greece are flagellated with multidrug resistant pathogens.

4.2. Anaerobic coverage

A questionable common practice is to cover anaerobes extensively, by adding metronidazole or clindamycin to the recommended antibiotic therapy. While it has been thought that anaerobic bacteria were frequent in pneumonia in the very old, particularly in AsP, recent microbiological data have reopened the debate [17,68], and previous post-mortem studies may have largely overestimated anaerobic involvement. Moreover, beta-lactam antibiotics in general, and the combination of amoxicillin and clavulanate in particular, have good activity against most anaerobic bacteria. Hence, adding metronidazole is not rational for supra-diaphragmatic infections, with the exception of abscesses. Recent guidelines propose no specific anti-anaerobic therapy for AsP [16]. Antibiotics targeting anaerobes may actually be harmful through their major impact on gut microbiome, depletion of anaerobic bacteria being associated with an increase in bacterial pneumonia, lung injury and mortality [68].

4.3. Duration

The duration of antibiotic treatment for pneumonia should not exceed five days if the course is favourable, whatever the age [69]. There are no data to support prolonged treatment in AsP or frailty. Inflammatory markers, especially PCT, could be useful to safely reduce the duration of antibiotic treatment [70].

4.4. Treatment failure

Apart from specific situations (multiple hospitalisations, chronic lung disease, bronchiectasis), antibiotic resistance to respiratory pathogens remains low, at least in Northern Europe, and non-sensitivity to the antibiotics administered is less frequent than diagnostic error. However, this is in contrast with other European countries where prevalence of antimicrobial resistance is very high. Hence optimizing antibiotic therapy is a global public health emergency [71]. When the evolution is unsatisfactory, a meticulous search for another diagnosis or complications should be preferred to “blind” antibiotic escalation. A chest CT scan may confirm the diagnosis and identify complications (empyema, abscess) or propose differential diagnoses (e.g. pulmonary embolism, heart failure, lung cancer). Diffuse lung disease (cryptogenic organising pneumonia, lung fibrosis, granulomatous disease) or unusual pathogens (mycobacteria, nocardia, pneumocystis) can also be suggested by the pattern and distribution of lung involvement on CT-scan.

5. Non-antibiotic treatment

5.1. Corticosteroids

Corticosteroids as adjuvant treatment in pneumonia reduce the risk of treatment failure, length of hospital stay, and time to clinical stability [72]. The impact on mortality is less obvious, the two more recent large clinical trials in severe CAP having conflicting results. A U.S. study included 586 patients admitted to the ICU and randomized to 40 mg methylprednisolone or placebo daily. There was no significant difference in 60-day mortality (16 % vs. 18 %, $p = 0.61$) [73]. In contrast, a French study randomized 800 patients admitted to the ICU to 200 mg hydrocortisone or placebo daily. The 28-day mortality was halved, and generally lower (6.3 % vs. 11.9 %, $P = 0.006$) [74]. The most plausible explanation for these conflicting results is the delay in starting treatment. The French trial administered steroids within 24 h of eligibility (median: 15 h) whereas the US trial allowed inclusion up to 96 h (median: 37 h). These results favour early initiation of hydrocortisone in adult patients with severe CAP. Unfortunately, the therapeutic effects of corticosteroids are often accompanied by clinically significant side effects, most of which are related to the dose and duration of therapy [75]. In existing literature, the duration of corticosteroid treatment is most frequently 7–10 days, however shorter duration (e.g. 4 days) appears to be effective in improving evolution [75], although the only published trial with a single dose of corticosteroid was negative [76]. Most adult trials used steroid doses equivalent to 40 mg to 50 mg of prednisone per day. The current U.S. guidelines [45] have not endorsed the routine use of corticosteroids for patients with severe CAP, while the European guidelines recommend their use only for severe CAP with concurrent shock [77]. Differentiating the phenotypes of responders and non-responders is a research priority [78,79]. The administration of corticosteroids must take into account the risk of gastric bleeding in these patients who also should receive anti-thrombotic prophylaxis (or treatment). The addition of proton pump inhibitor therapy at the acute phase of pneumonia seems reasonable in patients at risk of gastric bleeding (peptic ulcer disease, anti-thrombotic treatment) [80,81].

Conversely, there is no convincing evidence for large scale use of corticosteroids in non-severe pneumonia (i.e. outside intensive care units), because the small decrease in length of stay might be compensated by adverse events when corticosteroids are administered in a non-selected population with a high proportion of false diagnosis. Furthermore, in a recent meta-analysis of existing trials, corticosteroids in CAP were associated with a greater benefit in younger patients; the mortality benefit being not significant after 70 years [82].

5.2. Aspiration management

Aspiration is the main source of pneumonia in the very old.

Dysphagia, prior episodes of coughing on liquid (or food) intake, or gravity-dependent shadow distribution in Chest X rays are key points to suspect aspiration [83]. The management of AsP is complex and prognosis depends at least as much on treatment of the cause as on antibiotic therapy, since AsP frequently recurs despite microbiological success. Usual probabilistic treatment is recommended and there is no rationale to broaden antibiotic spectrum nor extend treatment duration in recurrence. Indeed, escalation of antibiotic treatment may affect the microbiota, select for microbiological resistance and thus compromise the success of future antibiotic therapy.

Aspiration prevention is paramount, requires comprehensive care, and should be conducted concurrently with antibiotic treatment. Installing patients in a seated, or at least semi-recumbent position is warranted, as patients in the supine position are prone to silent aspiration and early recurrence [83]. Prevention of recurrence also involves swallowing rehabilitation, meticulous oral care, meal and textures adaptation. Respiratory and general rehabilitation, active mobilization to prevent bed lying, avoidance of selected drugs (psychotropic drugs, proton pump inhibitors), and early re-nutrition are also important. [84]

While macro-aspiration results in chemical pneumonitis, it does not necessarily cause bacterial pneumonia and does not require systematic antibiotic treatment, as the acidic gastric fluid is usually sterile. Following an aspiration event, an expectant attitude, aiming to begin antibiotics only if deterioration of respiratory function or fever develops in the next 48 h should be preferred [85].

5.3. Prevention

In addition to managing the very common predisposing pathologies (Parkinson's or cerebro-vascular disease, heart failure...), measures to prevent the onset of pneumonia in the elderly are needed including stopping or reducing tobacco and alcohol consumption, improving oral and dental hygiene, physical exercise, avoiding contact with people suffering from respiratory infections combating undernutrition and iatrogenicity (proton pump inhibitors, neuroleptics, benzodiazepines, immunosuppressants), and vaccinations against pneumococcus, influenza, SARS-CoV-2, RSV [86] and soon metapneumovirus [87]. However pneumonia may sometimes not be preventable because of advanced ages and high comorbidity burden [88].

5.4. Oral care

Micro- or-macro- aspiration of oropharyngeal contents being the main source of bacterial infection of the lungs in the elderly, decreasing the concentration of pathogenic bacteria in the mouth is a logical prevention measure. This preventive strategy has recently proved highly effective to prevent ventilator-associated pneumonia [89]. Indeed, active aid in teeth brushing decreases incidence of pneumonia and pneumonia-related mortality in nursing-home residents [90]. However, intensive treatment and involvement of specialized dental personnel might be required to reach this benefit [91].

5.5. Nutritional support

The choice of the route of feeding is a key question after AsP. This complex decision involves both prognostic and ethical considerations, and requires a multidisciplinary approach respecting patient's wishes. Patients ingesting <60 % of the recommended daily allowance for more than one week have a worse prognosis [92]. There is considerable heterogeneity in practice regarding the use of enteral and parenteral nutrition (table 4). However, recent data demonstrate the importance of adequate nutritional intake, whatever the route, on short-term prognosis. A secondary analysis of a trial analysed patients with lower respiratory tract infection, randomised to receive individualised nutritional support (intervention group) or standard hospital diet (control group). Although the difference did not reach significance, mortality was halved

in the intervention group [93]. In a large observational study of very old Japanese patients with AsP, increased parenteral calories and amino acid doses were associated with reduced in-hospital mortality [94].

5.6. Pneumonia at the end of life

Pneumonia is a frequent terminal event in old and multimorbid patients, and there is no consensus on how to diagnose and treat it. Whether antibiotics should be prescribed to try to prolong survival or lessen patients symptoms remains controversial [95]. In this situation, palliative care should be promptly provided, and prescription of antibiotics used in a rational manner to limit antibiotic resistance [96]. Other medications (antipyretics, analgic drugs, anti-cholinergic drugs) and measures (stopping fluid administration) may be more indicated in terms of medical ethics [97].

5.7. Prevention of early complications

The geriatrician's added value in the care of pneumonia lies mainly in the early detection and management of co-morbidities. A comprehensive geriatric assessment includes addressing malnutrition, iatrogenesis, motor, nutritional, cognitive, psychological and social frailties. A particular attention should be paid to the detection, prevention and management of delirium, which is common in the course of pneumonia and is strongly associated with poor outcomes [98]. The presence of delirium during the acute phase of the infection should not prevent from motor rehabilitation and geriatric rehabilitation, as delirium does not influence the recovery trajectory of ADL functioning and quality of life [99].

5.8. Cardiovascular complications

The link between pneumonia and cardiovascular events is increasingly documented, for myocardial infarction [100], stroke [101], acute heart failure [102] and thromboembolism [103]. One-third of patients hospitalised for pneumonia will present a cardiovascular complication [104], the occurrence of which increases in-hospital mortality fivefold [105]. Thromboprophylaxis is recommended for hospitalised patients during the acute phase [106]. The value of antiplatelets drugs for the prevention of arterial events after pneumonia is suggested in observational [102,107] and interventional studies [108] and is currently being evaluated in on-going trials [109]. Older patients are particularly at risk for type 2 myocardial infarction, i.e. myocardial ischaemia without atherothrombotic events, secondary to an imbalance between myocardial oxygen supply and enhanced demand [110]. These functional myocardial infarctions are often painless and require close clinical monitoring. Although the cardiovascular risk persists for months after pneumonia [102] with a significantly higher risk of cardiovascular event (myocardial infarction, stroke) during two years [104], the vast majority of cardiac events occur on the first day following the diagnosis of pneumonia [111].

5.9. Functional decline

Functional decline following pneumonia is often severe, particularly in frail older adults. Sixty percent of older patients hospitalised for pneumonia will experience a deterioration in functional status. Frailty is a better predictor of functional trajectory than the severity of pneumonia itself, and preventive policies of early physiotherapy particularly benefit moderately frail or pre-frail patients [112].

In a longitudinal study evaluating cognitive trajectories five years after hospitalisation for pneumonia, a transient cognitive decline was found when compared with a matched control population [113]. However, it remains uncertain whether pneumonia itself or the iatrogenic effect of hospitalisation are responsible. A long-term impact of the infectious episode on neurocognitive impairment is debated [113,114].

Table 3
Common mistakes in antibiotic management of acute pneumonia in older patients.

| Common mistake | Alternative | Rational |
|---|--|---|
| Antibiotic treatment for >7 days | -Antibiotic treatment for 5 days if favourable evolution whatever age and frailty -CRP and PCT-guided treatment algorithms may help reducing the duration of antibiotic therapy | - Proven non-inferiority of short duration - Less impact on the microbiota |
| Addition of a specific anaerobic agent (metronidazole or clindamycin) for aspiration pneumonia (excluding pulmonary abscesses). | - Amoxicillin-clavulanate (or piperacillin-tazobactam if late nosocomial infection >5 days of hospital stay) | - Low involvement of anaerobes in non-abscessed pneumonia - Sensitivity of oral anaerobes to amoxicillin/clavulanic acid - Major impact on the gut microbiota |
| Therapeutic escalation in the case of positive respiratory samples taken under antibiotic treatment | Sample taken before any antibiotic treatment or in the event of microbiological failure only | - Respiratory samples taken while on antibiotics reflect the surviving flora of the upper airways but not necessarily the pathogen. |
| Therapeutic escalation due to aspiration recurrence | -Treatment of the cause (s) of aspiration -Short course of narrow-spectrum antibiotics | - This is a recurrence, not a microbiological failure. - Any escalation of treatment selects for resistance and affects the microbiota. |
| Therapeutic escalation due to rising CRP at 48-72h | -Clinical assessment of progress -Use of rapid kinetic parameters (leucocytes, procalcitonin) | - Slow kinetics of CRP with a peak delayed by 3 days |

The incidence of post-pneumonia neurovascular events could explain an increased risk of neurocognitive disorders of vascular origin [114].

The nutritional decline associated with pneumonia, due to hypercatabolism and intake deficiency, is often major and requires specific management. Nutritional parameters are highly predictive of post-pneumonia survival [115]. Appropriate early nutritional management, considering the risk associated with aspiration but also with the re-nutrition process (table 4), may limit sarcopenia induced by the infection.

6. Conclusion

Pneumonia remains the leading cause of infection-related death in older patients. Collaboration between geriatricians, internists and infectious disease physicians is paramount. The atypical presentation and simultaneous presence of comorbidities often compromise the accuracy of physical and radiological findings. To avoid both under and over diagnosis, the use of CT or lung ultrasound is recommended in uncertain cases. Aspiration is the predominant mechanism of pneumonia in frail older patients and *Enterobacteriaceae* coverage should be considered. However, extended anti-anaerobic coverage is not required. A 5-days treatment is frequently effective and limits the impact on microbiome. Early care is multidimensional and should involve consideration for cardiovascular involvement, prevention of delirium, and nutritional assessment and support. Given the heavy functional burden of pneumonia, early respiratory and motor rehabilitation are needed. As pneumonia is a frequent event at the end of life, palliative care should not be delayed.

Table 3

Table 4
Nutrition alternatives in patients with aspiration pneumonia.

| Nutrition mode | Advantages | Disadvantages | Preferred indications |
|---|--|---|---|
| Fasting | Lower risk of aspiration | Malnutrition | - Palliative care Or - Acute phase <72h |
| Oral diet +/- oral nutritional supplement | Eating pleasure | High risk of aspiration | - Palliative care Or - Satisfactory nutritional status and oral intake >60 % of recommended daily allowance |
| Enteral by nasogastric tube | Effective renutrition Prevention of villous atrophy | Risk of aspiration Discomfort Frequent accidental removal if delirium | - Nutritional support < 1 month And - 30–45° supine position possible |
| Enteral by gastrostomy | Effective renutrition Prevention of villous atrophy | Invasive procedure (percutaneous or endoscopic) | - Nutritional support >1 month And - Low aspiration risk |
| Enteral by jejunostomy | Effective renutrition Prevention of villous atrophy Lower risk of aspiration than other oral / enteral feeding methods | Surgical procedure | - Nutritional support >1 month And - High aspiration risk |
| Parenteral | Lower risk of aspiration | Frequent need of a central venous catheter Iatrogenic risk (metabolic disorders, catheter infection, volume overload) Accidental removal if delirium Lower quality of renutrition than enteral feeding | Acute reversible cause of non-functional digestive tract. |

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of competing interest

Authors disclose non conflicts of interest regarding this manuscript.

Ethical disclosure

Inform consent or institutional review board approval was not required because patients were not involved.

References

- [1] GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. *Lancet* 2020;396:1204–22. [https://doi.org/10.1016/S0140-6736\(20\)30925-9](https://doi.org/10.1016/S0140-6736(20)30925-9).
- [2] Janssens JP, Krause KH. Pneumonia in the very old. *Lancet Infect Diseases* 2004; 4:112–24.
- [3] Yoshimatsu Y, Melgaard D, Westergren A, Skrubbeltrang C, Smithard DG. The diagnosis of aspiration pneumonia in older persons: a systematic review. *Eur Geriatr Med* 2022;13:1071–80. <https://doi.org/10.1007/s41999-022-00689-3>.
- [4] Cillóniz C, Liapikou A, Martin-Loeches I, García-Vidal C, Gabarrús A, Ceccato A, et al. Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia. *PLoS ONE* 2018;13:e0200504. <https://doi.org/10.1371/journal.pone.0200504>.

- [5] Luna CM, Palma I, Niederman MS, Membriani E, Giovini V, Wiemken TL, et al. The impact of age and comorbidities on the mortality of patients of different age groups admitted with community-acquired pneumonia. *Ann Am Thorac Soc* 2016;13:1519–26. <https://doi.org/10.1513/AnnalsATS.201512-848OC>.
- [6] Mortensen EM, Kapoor WN, Chang CCH, Fine MJ. Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. *Clin Infect Dis* 2003;37:1617–24. <https://doi.org/10.1086/379712>.
- [7] Putot A, Putot S, Manckoundia P. Long-term survival after aspiration pneumonia in older inpatients: a comparative study. *J Am Med Dir Assoc* 2023. <https://doi.org/10.1016/j.jamda.2023.04.014>.
- [8] Torres A, Blasi F, Peetermans WE, Viegi G, Welte T. The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. *Eur J Clin Microbiol Infect Diseases* 2014;33:1065–79. <https://doi.org/10.1007/s10096-014-2067-1>.
- [9] Musher DM, Abers MS, Bartlett JG. Evolving understanding of the causes of pneumonia in adults, with special attention to the role of pneumococcus. *Clin Infect Diseases* 2017;65:1736–44. <https://doi.org/10.1093/cid/cix549>.
- [10] Fernández-Sabé N, Carratalà J, Rosón B, Dorca J, Verdaguier R, Manresa F, et al. Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. *Medicine (Baltimore)* 2003;82:159–69. <https://doi.org/10.1097/01.md.0000076005.64510.87>.
- [11] Meyer Sauter PM, Beeton ML. European society of clinical microbiology and infectious diseases (ESCMID) study group for mycoplasma and chlamydia infections (ESGMAC), and the ESGMAC mycoplasma pneumoniae surveillance (MAPS) study group. pneumonia outbreaks due to re-emergence of mycoplasma pneumoniae. *Lancet Microbe* 2024;5:e514. [https://doi.org/10.1016/S2666-5247\(23\)00406-8](https://doi.org/10.1016/S2666-5247(23)00406-8).
- [12] Samuelsson J, Payne Hallström L, Marrone G, Gomes Dias J. Legionnaires' disease in the EU/EEA*: increasing trend from 2017 to 2019. *Euro Surveill* 2023;28:2200114. <https://doi.org/10.2807/1560-7917.ES.2023.28.11.2200114>.
- [13] Haubitze S, Hitz F, Graedel L, Batschwaroff M, Wiemken TL, Peyrani P, et al. Ruling out legionella in community-acquired pneumonia. *Am J Med* 2014;127:1010. <https://doi.org/10.1016/j.amjmed.2014.03.042>. e11-19.
- [14] Stupka JE, Mortensen EM, Anzueto A, Restrepo MI. Community-acquired pneumonia in elderly patients. *Aging Health* 2009;5:763–74. <https://doi.org/10.2217/ah.09.74>.
- [15] Gallego M, Pomares X, Espasa M, Castañer E, Solé M, Suárez D, et al. Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors. *BMC Pulm Med* 2014;14:103. <https://doi.org/10.1186/1471-2466-14-103>.
- [16] Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the American thoracic society and infectious diseases society of America. *Am J Respir Crit Care Med* 2019;200:e45–67. <https://doi.org/10.1164/rccm.201908-1581ST>.
- [17] Marin-Corral J, Pascual-Guardia S, Amati F, Aliberti S, Masclans JR, Soni N, et al. Aspiration risk factors, microbiology, and empiric antibiotics for patients hospitalized with community-acquired pneumonia. *Chest* 2021;159:58–72. <https://doi.org/10.1016/j.chest.2020.06.079>.
- [18] Venturas JP, Richards GA, Feldman C. Severe community-acquired pneumonia at a tertiary academic hospital in Johannesburg, South Africa. *Respir Med* 2024;234:107823. <https://doi.org/10.1016/j.rmed.2024.107823>.
- [19] Peña-López Y, Sabater-Riera J, Raj P. Severe respiratory syncytial virus disease. *J Intensive Med* 2024;4:405–16. <https://doi.org/10.1016/j.jointm.2024.03.001>.
- [20] Calvet L, Lemiale V, Mokart D, Peter S, Peter P, Demoule A, et al. Interpretation of results of PCR and B-D-glucan for the diagnosis of pneumocystis jirovecii pneumonia in immunocompromised adults with acute respiratory failure. *Ann Intensive Care* 2024;14:120. <https://doi.org/10.1186/s13613-024-01337-8>.
- [21] Jones BE, Chapman AB, Ying J, Rutter ED, Nevers MR, Baker A, et al. Diagnostic discordance, uncertainty, and treatment ambiguity in community-acquired pneumonia: a national cohort study of 115 U.S. veterans affairs hospitals. *Ann Intern Med* 2024. <https://doi.org/10.7326/M23-2505>.
- [22] Harper C, Newton P. Clinical aspects of pneumonia in the elderly veteran. *J Am Geriatr Soc* 1989;37:867–72. <https://doi.org/10.1111/j.1532-5415.1989.tb02268.x>.
- [23] Laborde C, Deidda M, Bador J, Putot S, Manckoundia P, Putot A. Apyrexia improves the prognostic value of quick SOFA in older patients with acute pneumonia or bacteremic urinary tract infection. *Infection* 2022. <https://doi.org/10.1007/s15010-022-01953-1>.
- [24] Hyemard C, Breining A, Duc S, Kohel D, Dubos M, Prevel R, et al. Atypical presentation of bacteremia in older patients is a risk factor for death. *Am J Med* 2019;132:1344–52. <https://doi.org/10.1016/j.amjmed.2019.04.049>. e1.
- [25] Albaum MN, Hill LC, Murphy M, Li YH, Fuhrman CR, Britton CA, et al. Interobserver reliability of the chest radiograph in community-acquired pneumonia. PORT Investigators. *Chest* 1996;110:343–50.
- [26] Self WH, Courtney DM, McNaughton CD, Wunderink RG, Kline JA. High discordance of chest x-ray and computed tomography for detection of pulmonary opacities in ED patients: implications for diagnosing pneumonia. *Am J Emerg Med* 2013;31:401–5. <https://doi.org/10.1016/j.ajem.2012.08.041>.
- [27] Esayag Y, Nikitin I, Bar-Ziv J, Cytter R, Hadas-Halpern I, Zalut T, et al. Diagnostic value of chest radiographs in bedridden patients suspected of having pneumonia. *Am. J. Med.* 2010;123:88. <https://doi.org/10.1016/j.amjmed.2009.09.012>. e1-88.e5.
- [28] Prendki V, Scheffler M, Huttner B, Garin N, Herrmann F, Janssens JP, et al. Low-dose computed tomography for the diagnosis of pneumonia in elderly patients: a prospective, interventional cohort study. *Eur Respiratory J* 2018;51:1702375. <https://doi.org/10.1183/13993003.02375-2017>.
- [29] Demi L, Wolfram F, Klersy C, De Silvestri A, Ferretti VV, Muller M, et al. New international guidelines and consensus on the use of lung ultrasound. *J Ultrasound Medicine* 2023;42:309–44. <https://doi.org/10.1002/jum.16088>.
- [30] Ticinesi A, Lauretani F, Nouvenne A, Mori G, Chiussi G, Maggio M, et al. Lung ultrasound and chest x-ray for detecting pneumonia in an acute geriatric ward. *Medicine (Baltimore)* 2016;95:e4153. <https://doi.org/10.1097/MD.0000000000004153>.
- [31] Scarlata S, Okoye C, Zotti S, Lauretani F, Nouvenne A, Cerundolo N, et al. Advancing healthcare through thoracic ultrasound research in older patients. *Aging Clin Exp Res* 2023;35:2887–901. <https://doi.org/10.1007/s40520-023-02590-w>.
- [32] Prendki V, Garin N, Stirnemann J, Combesecure C, Platon A, Bernasconi E, et al. LOW-dose CT or Lung UltraSonography versus standard of care based-strategies for the diagnosis of pneumonia in the elderly: protocol for a multicentre randomised controlled trial (OCTOPLUS). *BMJ Open* 2022;12:e055869.
- [33] Prendki V, Malézieux-Picard A, Azurmendi L, Sanchez JC, Vuilleumier N, Carballo S, et al. Accuracy of C-reactive protein, procalcitonin, serum amyloid A and neopterin for low-dose CT-scan confirmed pneumonia in elderly patients: a prospective cohort study. *PLoS One* 2020;15:e0239606. <https://doi.org/10.1371/journal.pone.0239606>.
- [34] van Vugt SF, Broekhuizen BDL, Lammens C, Zuithoff NPA, de Jong PA, Coenen S, et al. Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study. *BMJ* 2013;346. <https://doi.org/10.1136/bmj.f2450>.
- [35] Minnaard MC, de Groot JAH, Hopstaken RM, Schierenberg A, de Wit NJ, Reitsma JB, et al. The added value of C-reactive protein measurement in diagnosing pneumonia in primary care: a meta-analysis of individual patient data. *CMAJ* 2017;189:E56–63. <https://doi.org/10.1503/cmaj.151163>.
- [36] García Vázquez E, Martínez JA, Mensa J, Sánchez F, Marcos MA, de Roux A, et al. C-reactive protein levels in community-acquired pneumonia. *Eur Respir J* 2003;21:702–5. <https://doi.org/10.1183/09031936.03.00080203>.
- [37] Azzini AM, Dorizzi RM, Sette P, Vecchi M, Coledan I, Righi E, et al. A 2020 review on the role of procalcitonin in different clinical settings: an update conducted with the tools of the evidence based laboratory medicine. *Ann Transl Med* 2020;8:610. <https://doi.org/10.21037/atm-20-1855>. 610.
- [38] Valenzuela-Méndez B, Valenzuela-Sánchez F, Rodríguez-Gutiérrez JF, Bohollo-de-Austria R, Estella A, Martínez-García P, et al. Host response dysregulations amongst adults hospitalized by influenza A H1N1 virus pneumonia: a prospective multicenter cohort study. *Eur J Intern Med* 2022;104:89–97. <https://doi.org/10.1016/j.ejim.2022.07.010>.
- [39] Pietrobon AJ, Teixeira FME, Sato MN. I mmunosenescence and inflamming: risk factors of severe COVID-19 in older people. *Front Immunol* 2020;11:579220. <https://doi.org/10.3389/fimmu.2020.579220>.
- [40] Putot A, Tetu J, Perrin S, Bailly H, Piroth L, Besancenot JF, et al. Impact of microbiological samples in the hospital management of community-acquired, nursing home-acquired and hospital-acquired pneumonia in older patients. *Eur J Clin Microbiol Infect Diseases* 2016. <https://doi.org/10.1007/s10096-015-2565-9>.
- [41] Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, et al. Guidelines for the management of adult lower respiratory tract infections - full version. *Clinical Microbiol Infect* 2011;17:E1–59. <https://doi.org/10.1111/j.1469-0691.2011.03672.x>.
- [42] Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update. *Thorax* 2009;64(3). <https://doi.org/10.1136/thx.2009.121434>. 2009Suppliii1-55.
- [43] Parente DM, Cunha CB, Mylonakis E, Timbrook TT. The clinical utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening to rule out MRSA pneumonia: a diagnostic meta-analysis with antimicrobial stewardship implications. *Clin Infect Dis* 2018;67:1–7. <https://doi.org/10.1093/cid/ciy024>.
- [44] Vidaur L, Totorika I, Montes M, Vicente D, Rello J, Cilla G. Human metapneumovirus as cause of severe community-acquired pneumonia in adults: insights from a ten-year molecular and epidemiological analysis. *Ann Intensive Care* 2019;9:86. <https://doi.org/10.1186/s13613-019-0559-y>.
- [45] Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, et al. Official American thoracic society/infectious diseases society of America/centers for disease control and prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. *clinfect diseases* 2017;64:e1–33. <https://doi.org/10.1093/cid/ciw694>.
- [46] Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. *New England J Med* 1997;336:243–50.
- [47] Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. *Thorax* 2003;58:377–82.
- [48] Parsonage M, Nathwani D, Davey P, Barlow G. Evaluation of the performance of CURB-65 with increasing age. *Clin Microbiol Infect* 2009;15:858–64. <https://doi.org/10.1111/j.1469-0691.2009.02908.x>.
- [49] Baek MS, Park S, Choi JH, Kim CH, Hyun IG. Mortality and prognostic prediction in very elderly patients with severe pneumonia. *J Intensive Care Med* 2019. <https://doi.org/10.1177/0885066619826045>. 088506661982604.
- [50] Ehsanpoor B, Vahidi E, Seyedhosseini J, Jahanshir A. Validity of SMART-COP score in prognosis and severity of community acquired pneumonia in the

- emergency department. *Am J Emerg Med* 2019;37:1450–4. <https://doi.org/10.1016/j.ajem.2018.10.044>.
- [51] Shirata M, Ito I, Ishida T, Tachibana H, Tanabe N, Konishi S, et al. Development and validation of a new scoring system for prognostic prediction of community-acquired pneumonia in older adults. *Sci Rep* 2021;11:23878. <https://doi.org/10.1038/s41598-021-03440-3>.
- [52] Kang Y, Fang XY, Wang D, Wang XJ. Activity of daily living upon admission is an independent predictor of in-hospital mortality in older patients with community-acquired pneumonia. *BMC Infect Dis* 2021;21:314. <https://doi.org/10.1186/s12879-021-06006-w>.
- [53] Pilotto A, Dini S, Daragiati J, Miolo M, Mion MM, Fontana A, et al. Combined use of the multidimensional prognostic index (MPI) and procalcitonin serum levels in predicting 1-month mortality risk in older patients hospitalized with community-acquired pneumonia (CAP): a prospective study. *Aging Clin Exp Res* 2018;30:193–7. <https://doi.org/10.1007/s40520-017-0759-y>.
- [54] Welker JA, Huston M, McCue JD. Antibiotic timing and errors in diagnosing pneumonia. *Arch Intern Med* 2008;168:351–6. <https://doi.org/10.1001/archinternmed.2007.84>.
- [55] Mertz D, Koller M, Haller P, Lampert ML, Plagge H, Hug B, et al. Outcomes of early switching from intravenous to oral antibiotics on medical wards. *J Antimicrob Chemother* 2009;64:188–99. <https://doi.org/10.1093/jac/dkp131>.
- [56] Kimura T, Ito M, Onozawa S. Switching from intravenous to oral antibiotics in hospitalized patients with community-acquired pneumonia: a real-world analysis 2010–2018. *J Infect Chemother* 2020;26:706–14. <https://doi.org/10.1016/j.jiac.2020.03.010>.
- [57] Alves J, Prendki V, Chedid M, Yahav D, Bosetti D, Rello J, et al. Challenges of antimicrobial stewardship among older adults. *Eur J Intern Med* 2024;124:5–13. <https://doi.org/10.1016/j.ejim.2024.01.009>.
- [58] Vidaur L, Eguibar I, Olazabal A, Aseguinolaza M, Leizaola O, Guridi A, et al. Impact of antimicrobial stewardship in organisms causing nosocomial infection among COVID-19 critically ill adults. *Eur J Intern Med* 2024;119:93–8. <https://doi.org/10.1016/j.ejim.2023.08.009>.
- [59] Faverio P, Aliberti S, Bellelli G, Suigo G, Lonni S, Pesci A, et al. The management of community-acquired pneumonia in the elderly. *Eur J Intern Med* 2014;25:312–9. <https://doi.org/10.1016/j.ejim.2013.12.001>.
- [60] Vieceli T, Rello J. Optimization of antimicrobial prescription in the hospital. *Eur J Intern Med* 2022;106:39–44. <https://doi.org/10.1016/j.ejim.2022.08.035>.
- [61] Fishbein SRS, Mahmud B, Dantas G. Antibiotic perturbations to the gut microbiome. *Nat Rev Microbiol* 2023;21:772–88. <https://doi.org/10.1038/s41579-023-00933-y>.
- [62] Daneman N, Lu H, Redelmeier DA. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. *BMJ Open* 2015;5:e010077. <https://doi.org/10.1136/bmjopen-2015-010077>.
- [63] Er AG, Alonso AAR, Marin-Leon I, Sayiner A, Bassetti S, Demirkan K, et al. Community-acquired pneumonia - an EFIM guideline critical appraisal adaptation for internists. *Eur J Intern Med* 2022;106:1–8. <https://doi.org/10.1016/j.ejim.2022.10.009>.
- [64] Waterer G. Macrolides in community-acquired pneumonia. *Lancet Respiratory Med* 2024;12:260–2. [https://doi.org/10.1016/S2213-2600\(23\)00434-4](https://doi.org/10.1016/S2213-2600(23)00434-4).
- [65] Postma DF, van Werkhoven CH, van Elden LJR, Thijsen SFT, Hoepelman AIM, Kluytmans JAJW, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. *N Engl J Med* 2015;372:1312–23. <https://doi.org/10.1056/NEJMoa1406330>.
- [66] Garin N, Genné D, Carballo S, Chuard C, Eich G, Hugli O, et al. β -lactam monotherapy vs β -lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. *JAMA Intern Med* 2014;174:1894–901. <https://doi.org/10.1001/jamainternmed.2014.4887>.
- [67] Bonaldo G, Andriani LA, D'Annibali O, Motola D, Vaccheri A. Cardiovascular safety of macrolide and fluorquinolone antibiotics: an analysis of the WHO database of adverse drug reactions. *Pharmacoepidemiol Drug Saf* 2019;28:1457–63. <https://doi.org/10.1002/pds.4873>.
- [68] Chanderraj R, Baker JM, Kay SG, Brown CA, Hinkle KJ, Fergle DJ, et al. In critically ill patients, anti-anaerobic antibiotics increase risk of adverse clinical outcomes. *Eur Respir J* 2023;61:2200910. <https://doi.org/10.1183/13993003.00910-2022>.
- [69] Dinh A, Ropers J, Duran C, Davido B, Deconinck L, Matt M, et al. Discontinuing β -lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. *Lancet* 2021;397:1195–203. [https://doi.org/10.1016/S0140-6736\(21\)00313-5](https://doi.org/10.1016/S0140-6736(21)00313-5).
- [70] Schuetz P, Müller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. *Cochrane Database Syst Rev* 2012. <https://doi.org/10.1002/14651858.CD007498.pub2>. CD007498.
- [71] Bassetti S, Tschudin-Sutter S, Egli A, Osthoff M. Optimizing antibiotic therapies to reduce the risk of bacterial resistance. *Eur J Intern Med* 2022;99:7–12. <https://doi.org/10.1016/j.ejim.2022.01.029>.
- [72] Ceccato A, Ferrer M, Barbata E, Torres A. Adjunctive therapies for community-acquired pneumonia. *Clin Chest Med* 2018;39:753–64. <https://doi.org/10.1016/j.ccm.2018.07.008>.
- [73] Meduri GU, Shih MC, Bridges L, Martin TJ, El-Solh A, Seam N, et al. Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. *Intensive Care Med* 2022;48:1009–23. <https://doi.org/10.1007/s00134-022-06684-3>.
- [74] Dequin PF, Meziani F, Quenot JP, Kamel T, Ricard JD, Badie J, et al. Hydrocortisone in severe community-acquired pneumonia. *N Engl J Med* 2023. <https://doi.org/10.1056/NEJMoa2215145>. NEJMoa2215145.
- [75] Stern A, Skalsky K, Avni T, Carrara E, Leibovici L, Paul M. Corticosteroids for pneumonia. *Cochrane Database Syst Rev* 2017. <https://doi.org/10.1002/14651858.CD007720.pub3>. 2017.
- [76] Marik P, Kraus P, Sribante J, Havlik I, Lipman J, Johnson DW. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. *Chest* 1993;104:389–92. <https://doi.org/10.1378/chest.104.2.389>.
- [77] Martin-Loeches I, Torres A, Nagavci B, Aliberti S, Antonelli M, Bassetti M, et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. *Eur Respiratory J* 2023;61. <https://doi.org/10.1183/13993003.00735-2022>.
- [78] Rello J, Waterer GW, Bourdiol A, Roquilly A. COVID-19, steroids and other immunomodulators: the jigsaw is not complete. *Anaesth Crit Care Pain Med* 2020;39:699–701. <https://doi.org/10.1016/j.accpm.2020.10.011>.
- [79] Bouras M, Rello J, Roquilly A. Steroids in severe community-acquired pneumonia: dangerous, worthless, or miracle cure? the roller coaster of clinical trials. *Anaesth Crit Care Pain Med* 2023;42:101253. <https://doi.org/10.1016/j.accpm.2023.101253>.
- [80] Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving Rivaroxaban or Aspirin. *Gastroenterology* 2019;157:682–91. <https://doi.org/10.1053/j.gastro.2019.05.056>. e2.
- [81] Kumar SS, Arvind S, Umpierrez AP. Things we do for No reason™: routine use of proton pump inhibitors for peptic ulcer prophylaxis in adults on high-dose corticosteroids. *J Hosp Med* 2023;18:630–2. <https://doi.org/10.1002/jhm.13095>.
- [82] Cheema HA, Musheer A, Ejaz A, Paracha AA, Shahid A, Rehman MEU, et al. Efficacy and safety of corticosteroids for the treatment of community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials. *J Crit Care* 2024;80:154507. <https://doi.org/10.1016/j.jccr.2023.154507>.
- [83] Ocropoma S, Restrepo MI. Severe aspiration pneumonia in the elderly. *J Intensive Med* 2024;4:307–17. <https://doi.org/10.1016/j.jointm.2023.12.009>.
- [84] Ebihara T. Comprehensive approaches to aspiration pneumonia and dysphagia in the elderly on the disease time-axis. *J Clin Med* 2022;11:5323. <https://doi.org/10.3390/jcm11185323>.
- [85] Mandell LA, Niederman MS. Aspiration pneumonia. *N Engl J Med* 2019;380:651–63. <https://doi.org/10.1056/NEJMra1714562>.
- [86] Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, et al. Efficacy and safety of respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons. *Clinical Infect Diseases* 2024;78:1732–44. <https://doi.org/10.1093/cid/ciae010>.
- [87] Troncoso-Bravo T, Ramírez MA, Loaiza RA, Román-Cárdenas C, Papazisis G, Garrido D, et al. Advancement in the development of mRNA-based vaccines for respiratory viruses. *Immunology* 2024;173:481–96. <https://doi.org/10.1111/imm.13844>.
- [88] Waterer GW, Self WH, Courtney DM, Grijalva CG, Balk RA, Girard TD, et al. Hospital deaths among adults with community-acquired pneumonia. *Chest* 2018;154:628–35. <https://doi.org/10.1016/j.chest.2018.05.021>.
- [89] Ehrenzeller S, Klompas M. Association between daily toothbrushing and hospital-acquired pneumonia: a systematic review and meta-analysis. *JAMA Intern Med* 2024;184:131–42. <https://doi.org/10.1001/jamainternmed.2023.6638>.
- [90] Yoneyama T, Yoshida M, Ohru T, Mukaiyama H, Okamoto H, Hoshiba K, et al. Oral care reduces pneumonia in older patients in nursing homes. *J Am Geriatr Soc* 2002;50:430–3. <https://doi.org/10.1046/j.1532-5415.2002.50106.x>.
- [91] Sjögren P, Wårdh I, Zimmerman M, Almståhl A, Wikström M. Oral care and mortality in older adults with pneumonia in hospitals or Nursing homes: systematic review and meta-analysis. *J Am Geriatr Soc* 2016;64:2109–15. <https://doi.org/10.1111/jgs.14260>.
- [92] Sobotka L, Schneider SM, Berner YN, Cederholm T, Krznaric Z, Shenkin A, et al. ESPEN guidelines on parenteral nutrition: geriatrics. *Clin Nutr* 2009;28:461–6. <https://doi.org/10.1016/j.clnu.2009.04.004>.
- [93] Baumgartner A, Hasenboehler F, Cantone J, Hersberger L, Bargetzi A, Bargetzi L, et al. Effect of nutritional support in patients with lower respiratory tract infection: secondary analysis of a randomized clinical trial. *Clin Nutrition* 2021;40:1843–50. <https://doi.org/10.1016/j.clnu.2020.10.009>.
- [94] Maeda K, Murotani K, Kamoshita S, Horikoshi Y, Kuroda A. Effect of parenteral energy or amino acid doses on in-hospital mortality among patients with aspiration pneumonia: a cohort medical claims database study. *J Gerontol: Series A* 2022;77:1683–90. <https://doi.org/10.1093/gerona/glab306>.
- [95] Levin PD, Sidor AE, Moses AE, Sprung CL. End-of-life treatment and bacterial antibiotic resistance. *Chest* 2010;138:588–94. <https://doi.org/10.1378/chest.09-2757>.
- [96] Datta R, Topal J, McManus D, Dembry LM, Quagliarello V, Juthani-Mehta M, et al. Perspectives on antimicrobial use at the end of life among antibiotic stewardship programs: a survey of the society for healthcare epidemiology of America research network. *Infect Control Hosp Epidemiol* 2019;40:1074–6. <https://doi.org/10.1017/ice.2019.194>.
- [97] van Esch HJ, van Zuylen L, Geijteman ECT, Oomen-de Hoop E, Huisman BAA, Noordzij-Nooteboom HS, et al. Effect of prophylactic subcutaneous scopolamine butylbromide on death rattle in patients at the end of life: the SILENCE randomized clinical trial. *JAMA* 2021;326:1268–76. <https://doi.org/10.1001/jama.2021.14785>.
- [98] Aliberti S, Bellelli G, Belotti M, Morandi A, Messinesi G, Annoni G, et al. Delirium symptoms during hospitalization predict long-term mortality in patients with

- severe pneumonia. *Aging Clin Exp Res* 2015;27:523–31. <https://doi.org/10.1007/s40520-014-0297-9>.
- [99] Minnema J, Polinder-Bos HA, Cesari M, Dockery F, Everink IHJ, Francis BN, et al. The impact of delirium on recovery in geriatric rehabilitation after acute infection. *J Am Med Dir Assoc* 2024;25:105002. <https://doi.org/10.1016/j.jamda.2024.03.113>.
- [100] Putot A, Chague F, Manckoundia P, Cottin Y, Zeller M. Post-infectious myocardial infarction: new insights for improved screening. *J Clin Med* 2019;8. <https://doi.org/10.3390/jcm8060827>.
- [101] Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. *New England J Med* 2004;351:2611–8.
- [102] VF Corrales-Medina, Musher DM, Shachkina S, Chirinos JA. Acute pneumonia and the cardiovascular system. *Lancet* 2013;381:496–505. [https://doi.org/10.1016/S0140-6736\(12\)61266-5](https://doi.org/10.1016/S0140-6736(12)61266-5).
- [103] Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. *Lancet* 2006;367:1075–9. [https://doi.org/10.1016/S0140-6736\(06\)68474-2](https://doi.org/10.1016/S0140-6736(06)68474-2).
- [104] VF Corrales-Medina, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang CCH, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. *JAMA* 2015;313:264–74. <https://doi.org/10.1001/jama.2014.18229>.
- [105] Violi F, Cangemi R, Falcone M, Taliani G, Pieralli F, Vannucchi V, et al. Cardiovascular complications and short-term mortality risk in community-acquired pneumonia. *Clin Infect Dis* 2017;64:1486–93. <https://doi.org/10.1093/cid/cix164>.
- [106] Hirsh J, Guyatt G, Albers GW, Harrington R, Schünemann HJ. Antithrombotic and thrombolytic therapy. *Chest* 2008;133:110S–2S. <https://doi.org/10.1378/chest.08-0652>.
- [107] Rögnvaldsson KG, Bjarnason A, Kristinsson K, Bragason HT, Erlendsson H, Þorgeirsson G, et al. Acetylsalicylic acid use is associated with improved survival in bacteremic pneumococcal pneumonia: a long-term nationwide study. *J Intern Med* 2022;292:321–32. <https://doi.org/10.1111/joim.13485>.
- [108] Oz F, Gul S, Kaya MG, Yazici M, Bulut I, Elitok A, et al. Does aspirin use prevent acute coronary syndrome in patients with pneumonia: multicenter prospective randomized trial. *Coron Artery Dis* 2013;24:231–7. <https://doi.org/10.1097/MCA.0b013e32835d7610>.
- [109] Derde L. Randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia. *Clinicaltrials.gov*; 2024.
- [110] Putot A, Putot S, Chagué F, Cottin Y, Zeller M, Manckoundia P. New horizons in type 2 myocardial infarction: pathogenesis, assessment and management of an emerging geriatric disease. *Age Ageing* 2022;51. <https://doi.org/10.1093/ageing/afac085>.
- [111] Corrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L, Fine MJ. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. *Circulation* 2012;125:773–81. <https://doi.org/10.1161/CIRCULATIONAHA.111.040766>.
- [112] Park CM, Dhawan R, Lie JJ, Sison SM, Kim W, Lee ES, et al. Functional status recovery trajectories in hospitalised older adults with pneumonia. *BMJ Open Respir Res* 2022;9:e001233. <https://doi.org/10.1136/bmjresp-2022-001233>.
- [113] Hendel MK, Rizzuto D, Grande G, Calderón-Larrañaga A, Laukka EJ, Fratiglioni L, et al. Impact of pneumonia on cognitive aging: a longitudinal propensity-matched cohort study. *J Gerontol A Biol Sci Med Sci* 2022;78:1453–60. <https://doi.org/10.1093/geron/glac253>.
- [114] Muzambi R, Bhaskaran K, Smeeth L, Brayne C, Chaturvedi N, Warren-Gash C. Assessment of common infections and incident dementia using UK primary and secondary care data: a historical cohort study. *Lancet Healthy Longevity* 2021;2:e426–35. [https://doi.org/10.1016/S2666-7568\(21\)00118-5](https://doi.org/10.1016/S2666-7568(21)00118-5).
- [115] Chen B, Liu W, Chen Y, She Q, Li M, Zhao H, et al. Effect of poor nutritional status and comorbidities on the occurrence and outcome of pneumonia in elderly adults. *Front Med (Lausanne)* 2021;8:719530. <https://doi.org/10.3389/fmed.2021.719530>.
- [116] SA expert Advisory Group on Antimicrobial Resistance, (SAAGAR). Community acquired pneumonia (Adults) Clinical Guideline 2021.
- [117] Lee MS, Oh JY, Kang CI, Kim ES, Park S, Rhee CK, et al. Guideline for antibiotic use in adults with community-acquired pneumonia. *Infect Chemother* 2018;50:160–98. <https://doi.org/10.3947/ic.2018.50.2.160>.
- [118] Chidiac C. Société de pathologie infectieuse de langue française, Agence française de sécurité sanitaire des produits de santé. [Systemic antibiotherapy for the treatment of lower respiratory tract infections. Community acquired pneumonia, acute exacerbation of obstructive chronic bronchitis. *Med Mal Infect* 2011;41:221–8. <https://doi.org/10.1016/j.medmal.2010.10.001>.
- [119] Ewig S, Kolditz M, Pletz M, Altiner A, Albrich W, Drömann D, et al. Management of adult community-acquired pneumonia and prevention - Update 2021 - guideline of the German respiratory society (DGP), the Paul-Ehrlich-society for chemotherapy (PEG), the German society for infectious diseases (DGI), the German society of medical intensive care and emergency medicine (DGIIN), the German virological society (DGV), the competence network CAPNETZ, the German college of general practitioners and family physicians (DEGAM), the German Society for geriatric medicine (DGG), the German palliative society (DGP), the Austrian society of pneumology society (ÖGP), the Austrian society for infectious and tropical diseases (ÖGIT), the Swiss respiratory society (SGP) and the Swiss society for infectious diseases society (SSI)]. *Pneumologie* 2021;75:665–729. <https://doi.org/10.1055/a-1497-0693>.
- [120] Mikasa K, Aoki N, Aoki Y, Abe S, Iwata S, Ouchi K, et al. JAID/JSC guidelines for the treatment of respiratory infectious diseases: the Japanese association for infectious diseases/Japanese society of chemotherapy – the JAID/JSC guide to clinical management of infectious disease/guideline-preparing committee respiratory infectious disease WG. *J Infect Chemother* 2016;22:S1–65. <https://doi.org/10.1016/j.jiac.2015.12.019>.
- [121] Boyles TH, Brink A, Calligaro GL, Cohen C, Dheda K, Maartens G, et al. South African guideline for the management of community-acquired pneumonia in adults. *J Thorac Dis* 2017;9:1469–502. <https://doi.org/10.21037/jtd.2017.05.31>.
- [122] Corrêa R de A, Costa AN, Lundgren F, Michelin L, Figueiredo MR, Holanda M, et al. 2018 recommendations for the management of community acquired pneumonia. *J Bras Pneumol* 2018;44:405–23. <https://doi.org/10.1590/S1806-37562018000000130>.
- [123] Menéndez R, Torres A, Aspa J, Capelastegui A, Prat C, Rodríguez de Castro F. Community-acquired pneumonia. New Guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). *Archivos de Bronconeumología (English Edition)* 2010;46:543–58. [https://doi.org/10.1016/S1579-2129\(11\)60008-6](https://doi.org/10.1016/S1579-2129(11)60008-6).